SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 200.79-0.2%Nov 14 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: WTDEC who wrote (20353)5/11/1998 6:48:00 AM
From: Henry Niman  Read Replies (3) of 32384
 
Times cover story is on wiping out cancer. Although it focuses on anti-angiogenesis, there is a section on various approaches. Here's what they say about chemoprevention:

Many breast cancers
depend on the female
hormone estrogen to
stimulate their
growth. Tamoxifen,
which acts as an
antiestrogen in the
breast, has been
shown to prevent the
development of this
form of cancer.
Preliminary evidence
suggests that a newer
compound,
raloxifene, may
confer a similar
benefit without
serious side effects.
Compounds know as
retinoids, derivatives
of vitamin A, can
prevent recurrence of
certain head and
neck cancers.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News